OLD Mission Capital LLC acquired a new stake in Biogen Inc (NASDAQ:BIIB) in the 4th quarter, according to its most recent filing with the SEC. The fund acquired 1,768 shares of the biotechnology company’s stock, valued at approximately $563,000.
Several other institutional investors and hedge funds have also modified their holdings of the stock. Teachers Advisors LLC grew its position in shares of Biogen by 23.7% in the 4th quarter. Teachers Advisors LLC now owns 432,572 shares of the biotechnology company’s stock valued at $137,804,000 after purchasing an additional 82,966 shares during the period. Captrust Financial Advisors acquired a new position in shares of Biogen in the 4th quarter valued at approximately $113,000. Sarissa Capital Management LP grew its position in shares of Biogen by 7.8% in the 4th quarter. Sarissa Capital Management LP now owns 413,858 shares of the biotechnology company’s stock valued at $131,842,000 after purchasing an additional 30,000 shares during the period. Raymond James & Associates boosted its position in Biogen by 0.8% during the 4th quarter. Raymond James & Associates now owns 335,295 shares of the biotechnology company’s stock worth $106,815,000 after acquiring an additional 2,604 shares during the last quarter. Finally, HBK Investments L P acquired a new position in Biogen during the 4th quarter worth approximately $9,143,000. Institutional investors and hedge funds own 88.96% of the company’s stock.
Shares of Biogen Inc (BIIB) opened at $287.62 on Friday. Biogen Inc has a 12 month low of $244.28 and a 12 month high of $370.57. The company has a quick ratio of 2.07, a current ratio of 2.34 and a debt-to-equity ratio of 0.47. The firm has a market capitalization of $60,655.03, a price-to-earnings ratio of 24.13, a P/E/G ratio of 1.58 and a beta of 0.90.
A number of equities analysts have weighed in on BIIB shares. Oppenheimer reaffirmed a “buy” rating and set a $350.00 price target on shares of Biogen in a research report on Wednesday, November 22nd. Mizuho set a $400.00 price target on Biogen and gave the stock a “buy” rating in a research report on Monday, November 27th. Sanford C. Bernstein set a $318.00 price target on Biogen and gave the stock a “buy” rating in a research report on Tuesday, November 28th. JPMorgan Chase & Co. set a $378.00 price target on Biogen and gave the stock a “buy” rating in a research report on Monday, November 27th. Finally, BMO Capital Markets reaffirmed a “buy” rating and set a $385.00 price target on shares of Biogen in a research report on Monday, November 27th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and twenty-two have assigned a buy rating to the stock. Biogen has a consensus rating of “Buy” and an average target price of $370.07.
In other Biogen news, EVP Alfred Sandrock sold 1,294 shares of the stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $298.85, for a total transaction of $386,711.90. Following the transaction, the executive vice president now owns 7,296 shares in the company, valued at approximately $2,180,409.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Robert W. Pangia sold 5,832 shares of the stock in a transaction on Tuesday, January 9th. The stock was sold at an average price of $329.65, for a total value of $1,922,518.80. Following the transaction, the director now owns 23,539 shares in the company, valued at approximately $7,759,631.35. The disclosure for this sale can be found here. In the last 90 days, insiders sold 8,128 shares of company stock worth $2,601,512. 0.25% of the stock is owned by company insiders.
Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).
Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.